Based in Jupiter Florida, GLG Pharma, Inc. (GLG) is a private, clinical-stage biotechnology company delivering next-generation therapies for hyper-proliferative diseases such as cancer (breast, ovarian, glioblastoma), polycystic kidney disease, psoriasis, Crohns disease and inflammatory bowel disease. Our therapies are precision medicines that target the STAT3 cancer gateway. We personalize therapy using integrative genomics powered, cell culture platform (Gx-C3TM) which enables us to capture hyper-proliferative patient cells from the body, culture and expand them ex-vivo in a biomimetic, three dimensional microenvironment without drift or loss of identity, and systematically screen them against our proprietary library of new chemical and repurposed small molecule Inhibitors to identify the most appropriate compound(s) for each patients disease. We are currently engaged in clinical trials for Chronic Lymphocytic Leukemia (CLL, GLG-801) and Triple Negative Breast Cancer (TNBC); also, GLG-302, as part of a Cancer Prevention Program in collaboration with the National Cancer Institute). For additional information visit www.glgpharma.com, connect on Twitter, Facebook, LinkedIn or call or write Richard Gabriel, CEO GLG Pharma, Inc. - 781-883-6639, [email protected]